Clearmind Medicine Inc. (NASDAQ:CMND) Stock Short Interest Report for September

Clearmind Medicine Inc. (NASDAQ:CMND) was the target of a significant decline in short interest in September. As of September 30th, there was short interest totaling 14,819 shares, a decline of 58.5% from the September 15th total of 35,733 shares. Based on an average daily volume of 259,644 shares, the short-interest ratio is presently 0.1 days. Approximately 11.4% of the shares of the company are sold short.

Clearmind Medicine Stock Performance

Shares of CMND stock traded down $0.01 during trading hours on Tuesday, hitting $6.54. The stock had a trading volume of 7,187 shares, compared to its average volume of 117,562. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.31 and a quick ratio of 4.31. The firm has a market capitalization of $3.31 million, a PE ratio of -0.16 and a beta of 0.93. The stock’s 50 day moving average is $10.23 and its 200 day moving average is $28.62. Clearmind Medicine has a twelve month low of $5.25 and a twelve month high of $3,840.00.

Clearmind Medicine (NASDAQ:CMND) last announced its earnings results on Thursday, September 10th. The company reported ($4.56) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Clearmind Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th.

Clearmind Medicine Company Profile

Clearmind Medicine Inc (NASDAQ: CMND) is a clinical-stage biotechnology company developing psychedelic-derived therapeutics for underserved health conditions. The company’s research focuses on creating proprietary compounds designed to address disorders involving addictive and compulsive behaviors.

Clearmind’s lead research program centers on MEAI, a proprietary psychedelic molecule being evaluated for potential use in alcohol use disorder and binge-related behaviors. The company has also investigated additional applications for its compounds, including treatments for obesity and other conditions associated with abnormal consumption patterns.

Clearmind advances its programs through preclinical research, intellectual-property development and clinical testing, with the goal of establishing new pharmaceutical treatments rather than providing psychedelic services directly.